Unicycive Therapeutics Inc (UNCY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Unicycive Therapeutics Inc (UNCY) has a cash flow conversion efficiency ratio of -0.143x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.60 Million) by net assets ($53.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Unicycive Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
Unicycive Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Unicycive Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Unicycive Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Unicycive Therapeutics Inc ranked by their cash flow conversion efficiency. Explore Unicycive Therapeutics Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FinLab AG
F:A7A
|
0.013x |
|
Tecogen Inc.
NYSE:TGEN
|
-0.120x |
|
Horizon Copper Corp.
V:HCU
|
-0.023x |
|
Agora S.A.
WAR:AGO
|
0.079x |
|
BlackRock Long-Term Municipal Advantage Trust
NYSE:BTA
|
0.021x |
|
Paragon Care Limited
F:PXS
|
0.001x |
|
Surteco Group SE
XETRA:SUR
|
0.048x |
|
First Farms A/S
CO:FFARMS
|
-0.033x |
Annual Cash Flow Conversion Efficiency for Unicycive Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Unicycive Therapeutics Inc from 2018 to 2025. View UNCY share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $30.20 Million | $-31.32 Million | -1.037x | +73.03% |
| 2024-12-31 | $7.43 Million | $-28.57 Million | -3.845x | -180.11% |
| 2023-12-31 | $-3.81 Million | $-18.28 Million | 4.800x | -85.71% |
| 2022-12-31 | $-466.00K | $-15.65 Million | 33.586x | +9699.95% |
| 2021-12-31 | $16.48 Million | $-5.77 Million | -0.350x | -164.05% |
| 2020-12-31 | $-2.67 Million | $-1.46 Million | 0.546x | -58.94% |
| 2019-12-31 | $-884.00K | $-1.18 Million | 1.330x | +107.01% |
| 2018-12-31 | $-1.21 Million | $-775.00K | 0.643x | -- |
About Unicycive Therapeutics Inc
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester deriv… Read more